Vitiligo exacerbation during upadacitinib treatment for atopic dermatitis and improvement following a switch to abrocitinib: a case report

This case highlights the differential effects of upadacitinib and abrocitinib, possibly due to their distinct JAK2 inhibition profiles. The findings underscore the importance of considering kinase selectivity when using JAK inhibitors in patients with overlapping immune-mediated skin disorders.